|Bid||98.42 x 800|
|Ask||105.88 x 1400|
|Day's Range||98.12 - 101.81|
|52 Week Range||76.34 - 186.82|
|Beta (5Y Monthly)||1.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||226.44|
PLANO, Texas, October 15, 2021--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl ("bardoxolone") and disease education data on Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2021 being held virtually from November 4 – 7, 2021.
Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.
PLANO, Texas, September 30, 2021--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that it has completed its pre-New Drug Application ("NDA") meeting with the United States Food and Drug Administration ("FDA") for omaveloxolone for the treatment of patients with Friedreich’s ataxia and reaffirmed its plan to submit an NDA in the first quarter of 2022.